EMA Clarifies Clinical Requirements for Fixed-Dose Combination Drugs

International Pharmaceutical Regulatory Monitor
A A
Sponsors seeking EU authorization to market fixed-dose drug combinations should conduct multiarm, randomized, controlled trials comparing the FDC with its individual components, the European Medicines Agency says.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00